Previvo Genetics, Inc.

previvo.com

Previvo is a medical device company that utilizes patented technology to facilitate the capture of embryos without the processes used with In Vitro Fertilization (IVF). Previvo Uterine Lavage is a novel medical device that enables the recovery of in vivo (inside the body) embryos from the uterus of a woman. The medical device includes an intrauterine Lavage Catheter, a Lavage Controller, and a collection system. Once embryos are recovered, they can be biopsied and screened for specific genetic diseases to assist families with fertility planning. Previvo Uterine Lavage offers a potentially more natural and healthier alternative to in vitro Fertilization (IVF) embryo collection processes.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech

ARBOR BIOTECHNOLOGIES ENTERS INTO AGREEMENT WITH ACUITAS THERAPEUTICS FOR LIPID NANOPARTICLE DELIVERY SYSTEM FOR USE IN RARE LIVER DISEASES

Arbor Biotechnologies Inc | August 29, 2022

news image

Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles. As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patien...

Read More

Cell and Gene Therapy

INDYGENEUS AI SECURES PATHOGEN SEQUENCING FOR COVID-19 GENOMIC SURVEILLANCE INITIATIVES

IndyGeneUS AI | May 20, 2021

news image

Through collaborations, IndyGeneUS AI has acquired genomic analysis and testing capabilities. This pathogen sequencing capacity has emerged at a critical moment in efforts to improve genomic surveillance and monitor COVID-19 variant strains across the continent. IndyGeneUS founder and CEO Yusuf Henriques emphasized the importance of this work. "COVID-19 and its variants pose a danger to the entire African continent, so we must act quickly. Our partners understand the urgency ...

Read More

Cell and Gene Therapy

SQZ BIOTECHNOLOGIES AND COLLABORATORS PUBLISH TECHNOLOGY REVIEW ON SQZ® APCS AND EFFECTIVE CD8 T CELL ACTIVATION

SQZ Biotechnologies | July 13, 2022

news image

SQZ Biotechnologies Company focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced the publication of a technical review examining the ability of SQZ® Antigen Presenting Cells to activate CD8 T cells through MHC-I antigen presentation, an approach that may enable a more powerful T cell response and infiltration into solid tumors. Published in ESMO’s Immuno-Oncology and Technology journal, the review further explores the advantages of t...

Read More

INTRAVACC'S CANDIDATE RSV VACCINE DEMONSTRATES SAFETY IN PHASE I TRIAL

Intravacc | August 18, 2020

news image

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced the publication in the medical journal Vaccine, of a clinical phase I study with its candidate Respiratory Syncytial Virus (RSV) vaccine. The vaccine showed excellent induction of immunogenicity after nasal administration to healthy adult volunteers (18-50 years). In addition, the Live Attenuated Vaccine (LAV), constructed with reverse genetics, appears to be safe and well-tolera...

Read More
news image

MedTech

ARBOR BIOTECHNOLOGIES ENTERS INTO AGREEMENT WITH ACUITAS THERAPEUTICS FOR LIPID NANOPARTICLE DELIVERY SYSTEM FOR USE IN RARE LIVER DISEASES

Arbor Biotechnologies Inc | August 29, 2022

Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles. As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patien...

Read More
news image

Cell and Gene Therapy

INDYGENEUS AI SECURES PATHOGEN SEQUENCING FOR COVID-19 GENOMIC SURVEILLANCE INITIATIVES

IndyGeneUS AI | May 20, 2021

Through collaborations, IndyGeneUS AI has acquired genomic analysis and testing capabilities. This pathogen sequencing capacity has emerged at a critical moment in efforts to improve genomic surveillance and monitor COVID-19 variant strains across the continent. IndyGeneUS founder and CEO Yusuf Henriques emphasized the importance of this work. "COVID-19 and its variants pose a danger to the entire African continent, so we must act quickly. Our partners understand the urgency ...

Read More
news image

Cell and Gene Therapy

SQZ BIOTECHNOLOGIES AND COLLABORATORS PUBLISH TECHNOLOGY REVIEW ON SQZ® APCS AND EFFECTIVE CD8 T CELL ACTIVATION

SQZ Biotechnologies | July 13, 2022

SQZ Biotechnologies Company focused on unlocking the full potential of cell therapies for multiple therapeutic areas, announced the publication of a technical review examining the ability of SQZ® Antigen Presenting Cells to activate CD8 T cells through MHC-I antigen presentation, an approach that may enable a more powerful T cell response and infiltration into solid tumors. Published in ESMO’s Immuno-Oncology and Technology journal, the review further explores the advantages of t...

Read More
news image

INTRAVACC'S CANDIDATE RSV VACCINE DEMONSTRATES SAFETY IN PHASE I TRIAL

Intravacc | August 18, 2020

Intravacc, a global leader in translational research and development of viral and bacterial vaccines, today announced the publication in the medical journal Vaccine, of a clinical phase I study with its candidate Respiratory Syncytial Virus (RSV) vaccine. The vaccine showed excellent induction of immunogenicity after nasal administration to healthy adult volunteers (18-50 years). In addition, the Live Attenuated Vaccine (LAV), constructed with reverse genetics, appears to be safe and well-tolera...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us